[6-K] NOVO NORDISK A S Current Report (Foreign Issuer)
Novo Nordisk A/S has reported insider dealing information in line with market abuse regulations. The company discloses that board member Stephan Engels purchased Novo Nordisk B shares on Nasdaq Copenhagen. He bought 6,450 shares at a price of DKK 312.50 per share, corresponding to an aggregated transaction value of DKK 2,015,625.00 on 17 November 2025. The report is made under Article 19 of EU Regulation No. 596/2014 on market abuse, which requires company insiders and their closely associated persons to notify transactions in the company’s shares.
- None.
- None.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
________________
FORM 6-K
________________
REPORT OF FOREIGN PRIVATE ISSUER
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
November 17, 2025
________________
NOVO NORDISK A/S
(Exact name of Registrant as specified in its charter)
Novo Allé 1
DK- 2880, Bagsvaerd
Denmark
(Address of principal executive offices)
________________
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F
| Form 20-F ☒ | Form 40-F ☐ |
Trading in Novo Nordisk shares by board members, executives and associated persons
Bagsværd, Denmark, 17 November 2025 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse. The company’s board members, executives and their associated persons have reported the transactions to Novo Nordisk.
Page 2 of 3
| 1 | Details of the person discharging managerial responsibilities/person closely associated | ||||
| a) | Name of the Board member/Executive/Associated Person | Stephan Engels | |||
| 2 | Reason for the notification | ||||
| a) | Position/status | Member of the Board of Directors | |||
| b) | Initial notification/Amendment | Initial notification | |||
| 3 | Details of the issuer | ||||
| a) | Name | Novo Nordisk A/S | |||
| b) | LEI | 549300DAQ1CVT6CXN342 | |||
| 4 | Details of the transaction(s) | ||||
| a) |
Description of the financial instrument, type of instrument, |
Shares | |||
| Identification code | Novo Nordisk B DK0062498333 | ||||
| b) | Nature of the transaction | Purchase of shares | |||
| c) | Price(s) and volume(s) | Price(s) | Volume(s) | ||
| DKK 312.50 | 6,450 |
||||
| d) |
Aggregated information · Aggregated volume · Price |
6,450 shares DKK 2,015,625.00 | |||
| e) | Date of the transaction | 2025-11-17 | |||
| f) | Place of the transaction | Nasdaq Copenhagen | |||
Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 78,400 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Instagram, X, LinkedIn and YouTube.
Page 3 of 3
Contacts for further information
| Media: | ||
Ambre James-Brown +45 3079 9289 abmo@novonordisk.com |
Liz Skrbkova (US) +1 609 917 0632 lzsk@novonordisk.com |
|
| Investors: | ||
Jacob Martin Wiborg Rode +45 3075 5956 jrde@novonordisk.com |
Sina Meyer +45 3079 6656 azey@novonordisk.com |
|
Max Ung +45 3077 6414 mxun@novonordisk.com |
Christoffer Sho Togo Tullin +45 3079 1471 cftu@novonordisk.com |
|
Alex Bruce +45 34 44 26 13 axeu@novonordisk.com |
Frederik Taylor Pitter +1 609 613 0568 fptr@novonordisk.com |
|
Novo Nordisk A/S Investor Relations |
Novo Allé 1 2880 Bagsværd Denmark |
Telephone: +45 4444 8888 |
www.novonordisk.com |
| Company announcement No 36 / 2025 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.
| Date: November 17, 2025 |
NOVO NORDISK A/S
Maziar Mike Doustdar Chief Executive Officer |
FAQ
What insider transaction did Novo Nordisk (NVO) report in this Form 6-K?
Novo Nordisk reported that board member Stephan Engels conducted an insider transaction involving the purchase of 6,450 Novo Nordisk B shares on Nasdaq Copenhagen.
What was the price and total value of Stephan Engels' Novo Nordisk share purchase?
Stephan Engels bought the shares at DKK 312.50 per share, for an aggregated transaction value of DKK 2,015,625.00.
When and where did the reported Novo Nordisk (NVO) insider transaction take place?
The transaction took place on 17 November 2025 on Nasdaq Copenhagen, involving Novo Nordisk B shares.
Why is Novo Nordisk disclosing this board member share purchase?
The disclosure is made in accordance with Article 19 of Regulation No. 596/2014 on market abuse, which requires reporting of transactions by board members, executives, and their associated persons in the company’s shares.
Which financial instrument is involved in this Novo Nordisk (NVO) insider transaction?
The transaction involves Novo Nordisk B shares, identified by the code DK0062498333, listed on Nasdaq Copenhagen.
Who should investors or media contact at Novo Nordisk regarding this announcement?
The announcement lists several contacts, including Media contacts Ambre James-Brown and Liz Skrbkova, and Investor Relations contacts such as Jacob Martin Wiborg Rode, Sina Meyer, and others, with telephone numbers and emails provided.
